SVB's failure could have ripple effects in biotech; the flaw with Medicare's approach to drug pricing negotiations

Taking stock of the drug industry, from the lab to the medicine chest

March 10, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | SVB, biotech's bank of choice, just failed. It could have ripple effects SVB provided financial services to nearly half the venture-backed technology and life sciences startups in 2022. By Adam Feuerstein and Damian Garde and Allison DeAngelis STAT+ | Several years later, AstraZeneca says its drug extends life for some early-stage lung cancers Several years after osimertinib was shown to deter recurrence of lung cancers, it wasn't known until now if it extended survival as well. By Angus Chen STAT+ | Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn't affect prices Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show those factors don't affect prices. By Joanne Silberner Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser